- Home
- SHOO vs DNLI Comparison
SHOO vs DNLI Comparison
Compare SHOO & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHOO
- DNLI
- Stock Information
- Founded
- SHOO 1990
- DNLI 2013
- Country
- SHOO United States
- DNLI United States
- Employees
- SHOO N/A
- DNLI N/A
- Industry
- SHOO Shoe Manufacturing
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SHOO Consumer Discretionary
- DNLI Health Care
- Exchange
- SHOO Nasdaq
- DNLI Nasdaq
- Market Cap
- SHOO 2.5B
- DNLI 2.1B
- IPO Year
- SHOO 1993
- DNLI 2017
- Fundamental
- Price
- SHOO $33.16
- DNLI $14.99
- Analyst Decision
- SHOO Buy
- DNLI Strong Buy
- Analyst Count
- SHOO 7
- DNLI 15
- Target Price
- SHOO $30.33
- DNLI $33.50
- AVG Volume (30 Days)
- SHOO 1.7M
- DNLI 2.1M
- Earning Date
- SHOO 11-06-2025
- DNLI 11-05-2025
- Dividend Yield
- SHOO 2.52%
- DNLI N/A
- EPS Growth
- SHOO N/A
- DNLI N/A
- EPS
- SHOO 1.28
- DNLI N/A
- Revenue
- SHOO $2,319,527,000.00
- DNLI N/A
- Revenue This Year
- SHOO $11.57
- DNLI N/A
- Revenue Next Year
- SHOO $10.13
- DNLI $95,463.19
- P/E Ratio
- SHOO $26.13
- DNLI N/A
- Revenue Growth
- SHOO 7.97
- DNLI N/A
- 52 Week Low
- SHOO $19.05
- DNLI $10.57
- 52 Week High
- SHOO $49.12
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- SHOO 62.18
- DNLI 57.22
- Support Level
- SHOO $32.96
- DNLI $12.58
- Resistance Level
- SHOO $34.95
- DNLI $15.75
- Average True Range (ATR)
- SHOO 0.95
- DNLI 0.65
- MACD
- SHOO -0.13
- DNLI 0.21
- Stochastic Oscillator
- SHOO 48.83
- DNLI 76.97
About SHOO Steven Madden Ltd.
Steven Madden Ltd designs and sells brand-name and private-label footwear and accessories. Its products are geared toward fashion-conscious adults and children. The company sells its products through department stores and other retailers as well as its stores and websites. The company's revenue comes from its operating segments: Wholesale Footwear, Wholesale Accessories or Apparel, Direct-to-Consumer, and Licensing. The wholesale footwear segment accounts for the majority of revenue.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.